AgomAb Therapeutics NV (‘AgomAb’) announced today the appointment of two new members to its senior team to further strengthen the company’s clinical, legal and corporate development capabilities.
– : 5 Posts
AgomAb Therapeutics N.V. (‘AgomAb’) announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.
AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.